246 related articles for article (PubMed ID: 14758432)
61. What vaccine product attributes do immunization program stakeholders value? Results from interviews in six low- and middle-income countries.
Kristensen DD; Bartholomew K; Villadiego S; Lorenson K
Vaccine; 2016 Dec; 34(50):6236-6242. PubMed ID: 27836438
[TBL] [Abstract][Full Text] [Related]
62. The introduction of new vaccines into developing countries. IV: Global Access Strategies.
Mahoney RT; Krattiger A; Clemens JD; Curtiss R
Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119
[TBL] [Abstract][Full Text] [Related]
63. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
64. Methodological issues and new developments in the economic evaluation of vaccines.
Beutels P; Van Doorslaer E; Van Damme P; Hall J
Expert Rev Vaccines; 2003 Oct; 2(5):649-60. PubMed ID: 14711326
[TBL] [Abstract][Full Text] [Related]
65. Acceptability and Feasibility of Delivering Pentavalent Vaccines in a Compact, Prefilled, Autodisable Device in Vietnam and Senegal.
Guillermet E; Dicko HM; Mai le TP; N'Diaye M; Hane F; Ba SO; Gomis K; Tho NT; Lien NT; Than PD; Dinh TV; Jaillard P; Gessner BD; Colombini A
PLoS One; 2015; 10(7):e0132292. PubMed ID: 26186456
[TBL] [Abstract][Full Text] [Related]
66. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
67. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis.
Hammerschmidt T; Bisanz H; Wutzler P
Vaccine; 2007 Oct; 25(42):7307-12. PubMed ID: 17881097
[TBL] [Abstract][Full Text] [Related]
68. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a world health organization-sponsored consultation.
Steele AD; Patel M; Parashar UD; Victor JC; Aguado T; Neuzil KM
J Infect Dis; 2009 Nov; 200 Suppl 1():S63-9. PubMed ID: 19817616
[TBL] [Abstract][Full Text] [Related]
69. Assessment of vaccine wastage during a pulse polio immunization programme in India.
Mukherjee A; Ahluwalia TP; Gaur LN; Mittal R; Kambo I; Saxena NC; Singh P
J Health Popul Nutr; 2004 Mar; 22(1):13-8. PubMed ID: 15190807
[TBL] [Abstract][Full Text] [Related]
70. Implementing the birth dose of hepatitis B vaccine in rural Indonesia.
Creati M; Saleh A; Ruff TA; Stewart T; Otto B; Sutanto A; Clements CJ
Vaccine; 2007 Aug; 25(32):5985-93. PubMed ID: 17604881
[TBL] [Abstract][Full Text] [Related]
71. Adsorption of (99m)Tc-radiopharmaceuticals onto injection vials and syringes.
Mushtaq A; Ur Rehman T; Safdar Mansur M; Jehangir M
J Nucl Med Technol; 2008 Jun; 36(2):91-4. PubMed ID: 18483140
[TBL] [Abstract][Full Text] [Related]
72. Vaccine wastage in Ghana, Mozambique, and Pakistan: An assessment of wastage rates for four vaccines and the context, causes, drivers, and knowledge, attitudes and practices for vaccine wastage.
Mvundura M; Ng J; Reynolds K; Theng Ng Y; Bawa J; Bambo M; Bonsu G; Payne J; Chua J; Guerette J; Odei Antwi-Agyei K; Ribe S; Chinavane D; Arhin-Wiredu K; Shah A; Sitoe J; Yunus S; Powelson J; Amponsa-Achiano K; Eshioramhe Kojak K; Fredick Dadzie J; Asghar N; Caetano Correa G; Robertson J
Vaccine; 2023 Jun; 41(28):4158-4169. PubMed ID: 37270365
[TBL] [Abstract][Full Text] [Related]
73. One size does not fit all: The impact of primary vaccine container size on vaccine distribution and delivery.
Haidari LA; Wahl B; Brown ST; Privor-Dumm L; Wallman-Stokes C; Gorham K; Connor DL; Wateska AR; Schreiber B; Dicko H; Jaillard P; Avella M; Lee BY
Vaccine; 2015 Jun; 33(28):3242-7. PubMed ID: 25889160
[TBL] [Abstract][Full Text] [Related]
74. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
Soriano-Gabarró M; Rosenstein N; LaForce FM
J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
[TBL] [Abstract][Full Text] [Related]
75. Healthcare worker safety is a pre-requisite for injection safety in developing countries.
Kermode M
Int J Infect Dis; 2004 Nov; 8(6):325-7. PubMed ID: 15494253
[TBL] [Abstract][Full Text] [Related]
76. A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years.
Kurugöl Z; Mutlubaş F; Ozacar T
Vaccine; 2005 Apr; 23(22):2876-80. PubMed ID: 15780736
[TBL] [Abstract][Full Text] [Related]
77. Paving the way for the introduction of new vaccines into developing countries.
Chabalgoity JA
Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986
[TBL] [Abstract][Full Text] [Related]
78. Chapter 15: HPV vaccine use in the developing world.
Kane MA; Sherris J; Coursaget P; Aguado T; Cutts F
Vaccine; 2006 Aug; 24 Suppl 3():S3/132-9. PubMed ID: 16950000
[TBL] [Abstract][Full Text] [Related]
79. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
[TBL] [Abstract][Full Text] [Related]
80. How important are airfreight rates and vaccine packaging in cost-saving efforts for the Expanded Programme on Immunization?
Schreuder B; Arentsen H; Matosse M
Bull World Health Organ; 1997; 75(4):315-21. PubMed ID: 9342890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
